Abstract
Bullous pemfigoid (BP), an autoimmune disorder, can also be induced by some medications. Vildagliptin is a new drug used to treat diabetes mellitus (DM). Recently, a few cases of vildagliptin-induced BP have been described in the literature. We report a patient with BP in which vildagliptin was thought to be as a possible causative agent. The awareness of BP development risk during gliptin therapy can prevent unnecessary usage of systemic drugs with serious side effects.
Keywords:
Bullous pemphigoid; gliptins; vildagliptin.
MeSH terms
-
Adamantane / adverse effects
-
Adamantane / analogs & derivatives*
-
Adamantane / therapeutic use
-
Administration, Cutaneous
-
Clobetasol / administration & dosage
-
Clobetasol / therapeutic use
-
Complement C3 / immunology
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Dipeptidyl-Peptidase IV Inhibitors / adverse effects*
-
Dipeptidyl-Peptidase IV Inhibitors / therapeutic use
-
Drug Eruptions / diagnosis*
-
Drug Eruptions / drug therapy
-
Drug Eruptions / immunology
-
Female
-
Fluorescent Antibody Technique
-
Gliclazide / therapeutic use
-
Glucocorticoids / administration & dosage
-
Glucocorticoids / therapeutic use
-
Humans
-
Hypoglycemic Agents / therapeutic use
-
Metformin / therapeutic use
-
Middle Aged
-
Nitriles / adverse effects*
-
Nitriles / therapeutic use
-
Pemphigoid, Bullous / chemically induced*
-
Pemphigoid, Bullous / diagnosis
-
Pemphigoid, Bullous / drug therapy
-
Pemphigoid, Bullous / immunology
-
Pyrrolidines / adverse effects*
-
Pyrrolidines / therapeutic use
-
Skin / immunology
-
Skin / pathology
-
Vildagliptin
-
Withholding Treatment
Substances
-
Complement C3
-
Dipeptidyl-Peptidase IV Inhibitors
-
Glucocorticoids
-
Hypoglycemic Agents
-
Nitriles
-
Pyrrolidines
-
Metformin
-
Clobetasol
-
Gliclazide
-
Vildagliptin
-
Adamantane